Amgen

Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Fierce Pharma
Amgen
Astellas
Japan
BeiGene
China
Flag link:
Who are the 10 Most Innovative Biopharma Companies?
Who are the 10 Most Innovative Biopharma Companies?
BioSpace
innovation
Regeneron
Verily
Illumina
Biogen
Bayer
Bluebird Bio
Novartis
GSK
Genentech
Amgen
Flag link:
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
drug pricing
Roche
Eli Lilly
Amgen
Alnylam
Sanofi
Flag link:
Merck, Lilly and Amgen square off in appeals court over drug pricing in TV ads
Merck, Lilly and Amgen square off in appeals court over drug pricing in TV ads
Fierce Pharma
Merck
Eli Lilly
Amgen
HHS
drug pricing
television ads
Flag link:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Flag link:
Two Big Drug Flops Show How Health-Care Economics Have Changed
Two Big Drug Flops Show How Health-Care Economics Have Changed
Bloomberg
drug pricing
Sanofi
Amgen
Praluent
Repatha
Flag link:
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Xtalks
Amgen
BeiGene
oncology
China
Flag link:
Is there a future for pharma in neuro?
Is there a future for pharma in neuro?
Fierce Biotech
Neuroscience
R&D
Eli Lilly
Amgen
GSK
Novartis
Flag link:
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Pharmaforum
Amgen
Allergan
biosimilar
Roche
Rituxan
Flag link:
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
Xconomy
osteoporosis
Amgen
Europe
romosozumab
Evenity
Flag link:
Amgen rejigs Bay Area presence with deal for new R&D facility
Amgen rejigs Bay Area presence with deal for new R&D facility
Fierce Biotech
Amgen
Bay Area
San Francisco
R&D
Flag link:
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid
Fierce Biotech
Amgen
ASH2019
bispecific antibodies
AMG 701
Multiple Myeloma
Flag link:
3 Biotechs Facing FDA Approvals by Year's End
3 Biotechs Facing FDA Approvals by Year's End
Motley Fool
FDA
Amgen
Vascepa
Allergan
migraines
ubrogepant
Intra-Cellular Therapies
lumateperone
schizophrenia
Flag link:
4 FDA Dates Biotech Investors Should Circle in December
4 FDA Dates Biotech Investors Should Circle in December
Motley Fool
FDA
Amgen
anti-inflammatories
ABP710
Bausch Health Companies
acne
IDP-123
Intra-Cellular Therapies
lumateperone
schizophrenia
Vascepa
Amarin
Flag link:
Top 7 Companies in Biotech Beach by Revenue
Top 7 Companies in Biotech Beach by Revenue
BioSpace
Biotech Beach
San Diego
California
Amgen
Neurocrine
Acadia Pharmaceuticals
Retrophin
Tocagen
Mirati Therapeutics
AnaptysBio
Flag link:
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
Fierce Pharma
Amgen
Enbrel
Abarca
PBMs
rheumatoid arthritis
Flag link:
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Fierce Pharma
Amgen
Otezla
Celgene
psoriasis
Flag link:
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Motley Fool
Amarin
Vascepa
M&A
Amgen
Novartis
Pfizer
Flag link:
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences
Motley Fool
biosimilars
FDA
Coherus Biosciences
Neulasta
Amgen
Flag link:
Hit by copycat meds, Amgen trims 172 more jobs, this time in operations, R&D and sales
Hit by copycat meds, Amgen trims 172 more jobs, this time in operations, R&D and sales
Fierce Pharma
Amgen
layoffs
R&D
drug reps
Flag link:

Pages